Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen, Takeda, UCB enrol first patient in Covid-19 global platform study
Three drugmakers are part of the COVID R&D Alliance, which was established in March this year to boost the study candidates without regard to company affiliation. The alliance,
Three drugmakers are part of the COVID R&D Alliance, which was established in March this year to boost the study candidates without regard to company affiliation. The alliance,
The FDA grants Breakthrough Therapy designation to new medicines that are intended to treat a serious condition and where clinical evidence indicates that the drug may demonstrate substantial
The mRNA-1273 is an mRNA vaccine against Covid-19 encoding for a prefusion stabilised form of the Spike (S) protein. It was co-developed by Moderna and investigators from NIAID’s
The company-sponsored study is being carried out in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and
As per terms of the deal, Sage will secure $1.525 in cash that includes an upfront payment of $875m and $650m equity investment, as well as potential milestone
The acquisition of TheraPharm provides Telix with access to a portfolio of patents, technologies, production systems, clinical data and know-how in relation to the use of Molecularly Targeted
CF, a rare and life-shortening genetic disease, that affects around 75,000 people across the globe. It is a progressive and multi-system disease that damages the lungs, liver, GI
The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics. ”We
1n 2019, Astellas and FibroGen have also received Japanese approval for roxadustat for the treatment of anaemia in adult patients with CKD and on dialysis. FibroGen now secures
The global Phase II clinical trial is a randomised, double-blind, placebo-controlled and parallel-group trial designed to evaluate the efficacy and safety of CT-P59 in combination with standard of